Praise be, loyal ‘Handmaid’s Tale’ fans: Propulsive final season promises a satisfying catharsis Praise be The Independent UK · Apr 7, 2025
'The Handmaid's Tale' Season 6 Review: Hulu's Brutal Dystopian Show Finally Gets An Ending After eight years of fascist dystopia, June Osborne finally gets to rest. Inverse · Apr 3, 2025
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities. MarketBeat · Apr 1, 2025
These 2 Buy-Rated Dividend Stocks Could Be Next in Line for a Trump Tariff Selloff. Should You Jump Ship Now? Trump’s proposed tariffs on pharmaceutical imports from countries like Ireland and India have sparked concerns for companies like Amgen and Gilead Sciences. Barchart · Mar 31, 2025
UNAIDS chief urges Donald Trump to make an 'amazing deal' to end HIV The UNAIDS director also warned that US funding cuts could be dire for global efforts to curb HIV. Euronews · Mar 25, 2025
AIDS pandemic risks 'resurging globally' amid US funding halt: UN The world risks returning to the worst days of the global AIDS pandemic following the sudden halt to US foreign aid funding, the UN's top AIDS official said Monday, warning millions would die. Radio France Internationale · Mar 24, 2025
UNAIDS director proposes that President Trump make an 'amazing deal' to end HIV The head of the U.N. AIDS agency says the sudden loss of American money has been “devastating” for efforts to stop HIV and will cost many lives of the world’s most vulnerable people The Independent UK · Mar 24, 2025
Gilead Sciences - Leader in HIV Medicines Summary Gilead Sciences (GILD) shows strong technical buy signals, with a 19.60% gain since Trend Seeker's buy signal on 1/27 and a 50.31% gain in the last year. The company offers a diverse portfolio of medicines for HIV, COVID-19, liver diseases, oncology, and more, with significant collaborations enhancing its pipeline.... Barchart · Mar 14, 2025
How Is Gilead Sciences' Stock Performance Compared to Other Pharmaceutical Stocks? As Gilead Sciences has outperformed its industry peers recently, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects. Barchart · Mar 6, 2025
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer MarketBeat · Feb 22, 2025
The Handmaid's Tale season 6: everything we know so far about the hit Hulu show’s return The Handmaid's Tale season 6 returns to Hulu on April 8 – here's everything we know about the dystopian drama's return. TechRadar · Feb 22, 2025
Stock Index Futures Slip on Trump Tariffs, Powell’s Testimony on Tap March S&P 500 E-Mini futures (ESH25) are down -0.33%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.44% this morning as investors digested another round of tariffs introduced by U.S. President Donald Trump and looked ahead to Federal Reserve Chair Jerome Powell’s congressional testimony as well as Wednesday’s release… Barchart · Feb 11, 2025
Gilead Sciences Stock: Is Wall Street Bullish or Bearish? Shares of Gilead Sciences have surpassed the broader market over the past year, and Wall Street analysts are reasonably upbeat about its future outlook. Barchart · Feb 3, 2025
Earnings Preview: What to Expect From Gilead Sciences’ Report Gilead Sciences is likely to report its fiscal fourth-quarter earnings next month, and analysts are expecting a modest fall in its earnings. Barchart · Jan 17, 2025
StockNews.com · Jan 7, 2025 3 Biotech Innovators Advancing Genetic Therapies The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global regulations. Considering the advancements, fundamentally solid biotech stocks Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN) are emerging as top choices for investors seeking transformative opportunities. Read further….
Barchart · Dec 5, 2024 Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector? Gilead Sciences has recently demonstrated strong performance, outperforming the broader healthcare sector, and analysts maintain a cautiously optimistic outlook on its future.
Benzinga · Dec 3, 2024 Looking At Gilead Sciences's Recent Unusual Options Activity Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences (NASDAQ:GILD).
The Independent UK · Dec 1, 2024 A twice-yearly shot could help end AIDS. But will it get to everyone who needs it? A twice-yearly shot that prevents HIV infections will be available at low cost in 120 poor countries
StockNews.com · Nov 29, 2024 3 Biotech Stocks with Promising Pipelines to Watch As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…
International Business Times · Nov 26, 2024 Fewest New HIV Cases Since Late 1980s: UNAIDS Report Fewer people contracted HIV last year than at any point since the rise of the disease in the late 1980s, the United Nations said Tuesday, warning that this decline was still far too slow.
International Business Times · Nov 26, 2024 'Remarkable Global Progress': HIV Cases And Deaths Declining The number of new HIV infections and deaths has fallen across the world, marking significant progress in the fight against the disease.
Barchart · Nov 8, 2024 Gilead Sciences Stock: Analyst Estimates & Ratings Gilead Sciences has underperformed the broader market over the past year, but Wall Street analysts are moderately optimistic about the stock’s prospects.
StockNews.com · Nov 1, 2024 3 Biotechnology Stocks With Promising Pipelines With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming. Therefore, it could be wise to invest in solid biotech stocks Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD) for substantial returns. Read more.
Barchart · Oct 23, 2024 3 Top Healthcare Stocks to Buy for Growth and Dividends Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.
Barchart · Oct 22, 2024 Gilead Sciences’ Quarterly Earnings Preview: What You Need to Know Gilead Sciences is scheduled to report its fiscal third-quarter earnings next month, and analysts anticipate a lower-double-digit drop in its EPS.